The evolution of drug–resistant malaria: the role of drug elimination half–life

Author:

Hastings Ian M.1,Watkins William M.2,White Nicholas J.34

Affiliation:

1. Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK

2. Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L3 5QA, UK

3. Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand

4. Centre for Tropical Diseases, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 9DU, UK

Abstract

This paper seeks to define and quantify the influence of drug elimination half–life on the evolution of antimalarial drug resistance. There are assumed to be three general classes of susceptibility of the malaria parasite Plasmodium falciparum to a drug: Res0 , the original, susceptible wildtype; Res1 , a group of intermediate levels of susceptibility that are more tolerant of the drug but still cleared by treatment; and Res2 , which is completely resistant to the drug. Res1 and Res2 resistance both evolve much faster if the antimalarial drug has a long half–life. We show that previous models have significantly underestimated the rate of evolution of Res2 resistance by omitting the effects of drug half–life. The methodology has been extended to investigate (i) the effects of using drugs in combination, particularly when the components have differing half–lives, and (ii) the specific example of the development of resistance to the antimalarial pyrimethamine–sulphadoxine. An important detail of the model is the development of drug resistance in two separate phases. In phase A, Res1 is spreading and replacing the original sensitive forms while Res2 remains at a low level. Phase B starts once parasites are selected that can escape drug action ( Res1 genotypes with borderline chemosensitivity, and Res2 ): these parasites are rapidly selected, a process that leads to widespread clinical failure. Drug treatment is clinically successful during phase A, and health workers may be unaware of the substantial changes in parasite population genetic structure that predicate the onset of phase B. Surveillance programs are essential, following the introduction of a new drug, to monitor effectively changes in treatment efficacy and thus provide advance warning of drug failure. The model is also applicable to the evolution of antibiotic resistance in bacteria: in particular, the need for these models to incorporate drug pharmacokinetics to avoid potentially large errors in their predictions.

Publisher

The Royal Society

Subject

General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3